Wong TY, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology. 2008;115:116–26.

Article  PubMed  Google Scholar 

Yamashiro K, Oishi A, Hata M, Takahashi A, Tsujikawa A. Visual acuity outcomes of anti-VEGF treatment for neovascular age-related macular degeneration in clinical trials. Jpn J Ophthalmol. 2021;65:741–60.

Article  PubMed  Google Scholar 

Nguyen QD, Das A, Do DV, Dugel PU, Gomes A, Holz FG, et al. Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration. Ophthalmology. 2020;127:963–76.

Article  PubMed  Google Scholar 

Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127:72–84.

Article  PubMed  Google Scholar 

Dugel PU, Singh RP, Koh A, Ogura Y, Weissgerber G, Gedif K, et al. HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2021;128:89–99.

Article  PubMed  Google Scholar 

Matsumoto H, Hoshino J, Mukai R, Nakamura K, Akiyama H. Short-term outcomes of intravitreal brolucizumab for treatment-naive neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy. Sci Rep. 2021;11:6759.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Matsumoto H, Hoshino J, Mukai R, Nakamura K, Akiyama H. One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naive neovascular age-related macular degeneration with type 1 macular neovascularization. Sci Rep. 2022;12:8195.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Matsumoto H, Hoshino J, Nakamura K, Akiyama H. Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naive neovascular age-related macular degeneration with type 1 macular neovascularization. Sci Rep. 2023;13:3249.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Singer M, Albini TA, Seres A, Baumal CR, Parikh S, Gale R, et al. Clinical characteristics and outcomes of eyes with intraocular inflammation after brolucizumab: post hoc analysis of HAWK and HARRIER. Ophthalmol Retina. 2022;6:97–108.

Article  PubMed  Google Scholar 

Regula JT, von Lundh P, Foxton R, Barathi VA, Cheung CM, Bo Tun SB, et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med. 2016;8:1265–88.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729–40.

Article  PubMed  CAS  Google Scholar 

Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, et al. TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2. Ophthalmology. 2024;131:914–26.

Article  PubMed  Google Scholar 

Cheung CMG, Guymer RH, Demetriades AM, Margaron P, Quezada Ruiz C, Silverman D et al. Faricimab in neovascular age related macular degeneration (nAMD): efficacy, safety, and durability through week 48 in the phase 3 TENAYA and LUCERNE trials. Paper presented at The 22nd EURETINA Congress; September 1–4, 2022; Hamburg, German. Accessed October 30, 2024. https://euretina.softr.app/abstract?recordId=rec45rTrXZDtnpCsX.

Lim JI, Margaron P, Souverain A, Yang M, Shildkrot YE, Kotecha A et al. Greater reduction in pigment epithelial detachment size with faricimab vs aflibercept during head-to-head dosing in patients with nAMD. Paper presented at: The 56th Retina Society Annual Scientific Meeting; October 13, 2023; New York, NY. Accessed October 30, 2024. https://www.retinasociety.org/content/documents/rs_2023_nyc_program_final_web4lb.pdf

Matsumoto H, Hoshino J, Nakamura K, Akiyama H. One-year results of treat-and-extend regimen with intravitreal faricimab for treatment-naive neovascular age-related macular degeneration. Jpn J Ophthalmol. 2024;68:83–90.

Article  PubMed  CAS  Google Scholar 

Ota H, Takeuchi J, Nakano Y, Horiguchi E, Taki Y, Ito Y, et al. Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration. Jpn J Ophthalmol. 2022;66:278–84.

Article  PubMed  CAS  Google Scholar 

Kitajima Y, Maruyama-Inoue M, Ikeda S, Ito A, Inoue T, Yanagi Y, et al. Short-term outcomes of switching to brolucizumab in Japanese patients with neovascular age-related macular degeneration. Jpn J Ophthalmol. 2022;66:511–7.

Article  PubMed  CAS  Google Scholar 

Ueda-Consolvo T, Tanigichi A, Numata A, Oiwake T, Nakamura T, Ishida M, et al. Switching to brolucizumab from aflibercept in age-related macular degeneration with type 1 macular neovascularization and polypoidal choroidal vasculopathy: an 18-month follow-up study. Graefes Arch Clin Exp Ophthalmol. 2023;261:345–52.

Article  PubMed  CAS  Google Scholar 

Kikushima W, Sakurada Y, Fukuda Y, Matsubara M, Kotoda Y, Sugiyama A, et al. A treat-and-extend regimen of intravitreal brolucizumab for exudative age-related macular degeneration refractory to aflibercept: a 12-month result. Pharmaceuticals (Basel). 2023;16:562.

Article  PubMed  CAS  Google Scholar 

Kataoka K, Itagaki K, Hashiya N, Wakugawa S, Tanaka K, Nakayama M, et al. Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2024;262:43–51.

Article  PubMed  CAS  Google Scholar 

Tamiya R, Hata M, Tanaka A, Tsuchikawa M, Ueda-Arakawa N, Tamura H, et al. Therapeutic effects of faricimab on aflibercept-refractory age-related macular degeneration. Sci Rep. 2023;13:21128.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Schneider M, Bjerager J, Hodzic-Hadzibegovic D, Klefter ON, Subhi Y, Hajari J. Short-term outcomes of treatment switch to faricimab in patients with aflibercept-resistant neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2024;262:2153–62.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Rush RB. One-year outcomes of faricimab treatment for aflibercept-resistant neovascular age-related macular degeneration. Clin Ophthalmol. 2023;17:2201–8.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yanai H. Statcel—the useful add-in software forms on Excel. 4th ed. Tokyo: OMS; 2015. (in Japanese).

Google Scholar 

Matsumoto H, Hoshino J, Nakamura K, Nagashima T, Akiyama H. Short-term outcomes of intravitreal faricimab for treatment-naive neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2023;261:2945–52.

Article  PubMed  CAS  Google Scholar 

Moon BH, Kim Y, Kim SY. Twenty years of anti-vascular endothelial growth factor therapeutics in neovascular age-related macular degeneration treatment. Int J Mol Sci. 2023;24:13004.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Joussen AM, Ricci F, Paris LP, Korn C, Quezada-Ruiz C, Zarbin M. Angiopoietin/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data. Eye (Lond). 2021;35:1305–16.

Article  PubMed  Google Scholar 

Jaffe GJ, Martin DF, Toth CA, Daniel E, Maguire MG, Ying GS, et al. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2013;120:1860–70.

Article  PubMed  Google Scholar 

Waldstein SM, Simader C, Staurenghi G, Chong NV, Mitchell P, Jaffe GJ, et al. Morphology and visual acuity in aflibercept and ranibizumab therapy for neovascular age-related macular degeneration in the VIEW trials. Ophthalmology. 2016;123:1521–9.

Article  PubMed  Google Scholar 

Schmidt-Erfurth U, Waldstein SM. A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog Retin Eye Res. 2016;50:1–24.

Article  PubMed  CAS  Google Scholar 

Holekamp NM, Sadda S, Sarraf D, Guymer R, Hill L, Blotner S, et al. Effect of residual retinal fluid on visual function in Ranibizumab-treated neovascular age-related Macular Degeneration. Am J Ophthalmol. 2022;233:8–17.

Article  PubMed  CAS  Google Scholar 

Schmidt-Erfurth U, Muly